VOR — Vor Biopharma Inc.
4 mentions in the last 24 hours · 0.02% of all mentions
Why people talked about VOR (2026-10-30)
- VOR Biopharma reported Q3 2026 results with an adjusted EPS of -$0.90, missing estimates by 21.6%.
- The company reported zero revenue and had no analyst estimates published for revenue.
- VOR announced the full enrollment of the UPSTREAM MG Phase 3 trial with topline data expected in H1 2027.
| Bluesky | 3 | community |
| RSS Bundle | 1 | news |